

Joji Tani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1821402/publications.pdf>

Version: 2024-02-01

88
papers

1,416
citations

361413

20
h-index

414414

32
g-index

89
all docs

89
docs citations

89
times ranked

1764
citing authors

#	ARTICLE	IF	CITATIONS
1	Does first-line treatment have prognostic impact for unresectable HCC? Atezolizumab plus bevacizumab versus lenvatinib. <i>Cancer Medicine</i> , 2023, 12, 325-334.	2.8	25
2	Wafer paper and ring-mounted polyglycolic acid sheet method for shielding artificial gastric floor. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2022, 31, 548-555.	1.2	3
3	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. <i>Cancer Reports</i> , 2022, 5, e1464.	1.4	43
4	Long-term outcomes of over-the-scope clip for refractory gastrointestinal diseases. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2022, 31, 628-634.	1.2	5
5	Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1667.	4.1	2
6	Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. <i>Hepatology Research</i> , 2022, 52, 462-470.	3.4	18
7	Can microRNA-96-5p serve as a therapeutic molecule in the near future?. <i>Hepatology Research</i> , 2022, 52, 3-4.	3.4	0
8	Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells. <i>Anticancer Research</i> , 2022, 42, 1263-1275.	1.1	2
9	Clinical features of hepatic dysfunction caused by immune checkpoint inhibitors and treatment of refractory cases. <i>Acta Hepatologica Japonica</i> , 2022, 63, 107-119.	0.1	0
10	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC stage patients classified as beyond up to seven criteria – Multicenter analysis. <i>Hepatology Research</i> , 2022, 52, 308-316.	3.4	25
11	Telomerase Reverse Transcriptase Promoter Mutations in Human Hepatobiliary, Pancreatic and Gastrointestinal Cancer Cell Lines. <i>In Vivo</i> , 2022, 36, 94-102.	1.3	3
12	Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. <i>Cancer Medicine</i> , 2022, 11, 3796-3808.	2.8	21
13	C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. <i>Scientific Reports</i> , 2022, 12, 8421.	3.3	4
14	Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. <i>Hepatology Research</i> , 2022, 52, 773-783.	3.4	34
15	Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1812-1819.	2.8	28
16	Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by direct-acting antiviral therapies. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1126-1135.	2.8	1
17	Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis. <i>Hepatology Research</i> , 2021, 51, 201-215.	3.4	22
18	Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study. <i>Infectious Diseases and Therapy</i> , 2021, 10, 269-280.	4.0	0

#	ARTICLE	IF	CITATIONS
19	Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma. <i>Gastroenterology Report</i> , 2021, 9, 133-138.	1.3	21
20	A case report of granulocyte colony-stimulating factor-producing hepatocellular carcinoma that recurred after long-term complete response. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 204-211.	0.8	2
21	Association between microRNA-527 and glypican-3 in hepatocellular carcinoma. <i>Oncology Letters</i> , 2021, 21, 229.	1.8	3
22	What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?. <i>Liver Cancer</i> , 2021, 10, 115-125.	7.7	12
23	Diaphragmatic Hernia after Radiofrequency Ablation. <i>Diagnostics</i> , 2021, 11, 307.	2.6	1
24	Albumin platelet product as a novel score for liver fibrosis stage and prognosis. <i>Scientific Reports</i> , 2021, 11, 5345.	3.3	4
25	Prognosis of probable autoimmune hepatitis patients: a single-center study in Japan. <i>Internal and Emergency Medicine</i> , 2021, 16, 2155-2162.	2.0	2
26	MicroRNA Interference in Hepatic Host-Pathogen Interactions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3554.	4.1	14
27	Galectin-9 suppresses the tumor growth of colon cancer <i>in vitro</i> and <i>in vivo</i> . <i>Oncology Reports</i> , 2021, 45, .	2.6	15
28	Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. <i>Cancers</i> , 2021, 13, 2257.	3.7	1
29	Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5801.	4.1	182
30	Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. <i>Hepatology Research</i> , 2021, 51, 880-889.	3.4	15
31	Efforts to identify HCV antibody-positive patients in a medium-sized hospital by "Team hepatitis" composed of hospital staff with a hepatitis medical care coordinator. <i>Acta Hepatologica Japonica</i> , 2021, 62, 337-348.	0.1	3
32	White Spot, a Novel Endoscopic Finding, May Be Associated with Acid-Suppressing Agents and Hypergastrinemia. <i>Journal of Clinical Medicine</i> , 2021, 10, 2625.	2.4	1
33	Multimodal treatment involving molecular targeted agents and on-demand transcatheter arterial chemoembolization for advanced hepatocellular carcinoma: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 15, 154.	1.0	3
34	Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. <i>Liver International</i> , 2021, 41, 2997-3008.	3.9	18
35	Gastrointestinal Residue Removal Using a Balloon Overtube under Ultrathin Endoscopic Navigation: Ex Vivo and In Vivo Experimental Studies. <i>Journal of Clinical Medicine</i> , 2021, 10, 3796.	2.4	0
36	Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. <i>Scientific Reports</i> , 2021, 11, 16663.	3.3	30

#	ARTICLE	IF	CITATIONS
37	Efficacy of Combined Therapy with Drug-Eluting Beads-Transcatheter Arterial Chemoembolization Followed by Conventional Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multi-Center Study. <i>Cancers</i> , 2021, 13, 4605.	3.7	3
38	Effect of pegylated interferon alfa-2a in HBeAg-negative chronic hepatitis B during and 48 weeks after off-treatment follow-up: the limitation of pre-treatment HBsAg load for the seroclearance of HBsAg. <i>Internal and Emergency Medicine</i> , 2021, 16, 1559-1565.	2.0	6
39	MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review. <i>Cancers</i> , 2021, 13, 514.	3.7	63
40	L-carnitine reduces hospital admissions in patients with hepatic encephalopathy. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 32, 288-293.	1.6	4
41	Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13071.	4.1	14
42	Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 855-861.	2.8	23
43	Role of microRNA-210-3p in hepatitis B virus-related hepatocellular carcinoma. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G401-G409.	3.4	26
44	Clinical outcomes of hepatitis C virus elimination using glecaprevir and pibrentasvir in hemodialysis patients: A multicenter study. <i>Hepatology Research</i> , 2020, 50, 557-564.	3.4	4
45	Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1229-1237.	2.8	13
46	Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study. <i>Infectious Diseases and Therapy</i> , 2020, 9, 851-866.	4.0	16
47	Negative-pressure box under continuous suction for shielding against aerosols produced by patients with COVID-19 during abdominal ultrasound-guided intervention. <i>Digestive and Liver Disease</i> , 2020, 52, 1080-1081.	0.9	0
48	The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. <i>Hepatology International</i> , 2020, 14, 225-238.	4.2	25
49	Guidewire-assisted over-the-scope clip delivery method into the distal intestine: a case series. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2020, , 1-6.	1.2	2
50	Efficacy of crystal violet for identifying the distal end in esophageal submucosal tunnel resection. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2020, 30, 1-6.	1.2	1
51	Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: A large, multicenter study from Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1420-1425.	2.8	3
52	Outcomes of Endoscopic Submucosal Dissection for Subepithelial Lesions Localized Within the Submucosa, Including Neuroendocrine Tumors: A Multicenter Prospective Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 41-49.	0.9	7
53	Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study. <i>Oncology Letters</i> , 2020, 19, 2205-2212.	1.8	26
54	Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma. <i>Oncology Letters</i> , 2020, 20, 1727-1733.	1.8	10

#	ARTICLE	IF	CITATIONS
55	Aspirin inhibits hepatocellular carcinoma cell proliferation in vitro and in vivo via inducing cell cycle arrest and apoptosis. <i>Oncology Reports</i> , 2020, 44, 457-468.	2.6	17
56	Antihypertensive drug telmisartan inhibits cell proliferation of gastrointestinal stromal tumor cells in vitro. <i>Molecular Medicine Reports</i> , 2020, 22, 1063-1071.	2.4	6
57	Serum microRNA-125a-5p as a potential biomarker of HCV-associated hepatocellular carcinoma. <i>Oncology Letters</i> , 2019, 18, 882-890.	1.8	18
58	Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2 infected patients in a real-world setting in Japan. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1266-1275.	2.0	13
59	Prediction of Transplant-Free Survival through Albumin-Bilirubin Score in Primary Biliary Cholangitis. <i>Journal of Clinical Medicine</i> , 2019, 8, 1258.	2.4	11
60	Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion. <i>Molecular and Clinical Oncology</i> , 2019, 11, 447-454.	1.0	5
61	Endoscopic Submucosal Dissection for Neoplasia of the Greater Curvature of the Upper and Middle Stomach: J-shaped Superficial Cutting and Splashed Dissection. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 397-404.	0.9	2
62	Correlation between serum galectin-9 levels and liver fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 492-499.	2.8	22
63	Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV. <i>Internal Medicine</i> , 2018, 57, 1101-1104.	0.7	4
64	Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1940.	4.1	9
65	Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan. <i>Journal of Gastroenterology</i> , 2018, 53, 1276-1284.	5.1	25
66	Galectin-9 ameliorates fulminant liver injury. <i>Molecular Medicine Reports</i> , 2017, 16, 36-42.	2.4	12
67	MicroRNA profile of hepatic epithelioid hemangioendothelioma: A case report. <i>Oncology Letters</i> , 2017, 13, 1655-1659.	1.8	1
68	Induction of apoptosis by Galectin-9 in liver metastatic cancer cells: In vitro study. <i>International Journal of Oncology</i> , 2017, 51, 607-614.	3.3	11
69	Characteristics and Prognosis of Hepatocellular Carcinoma in Japanese Patients Undergoing Dialysis. <i>Therapeutic Apheresis and Dialysis</i> , 2017, 21, 465-472.	0.9	12
70	Efficacy and safety of elbasvir and grazoprevir for chronic hepatitis C patients with chronic kidney disease. <i>Acta Hepatologica Japonica</i> , 2017, 58, 678-680.	0.1	1
71	Cancer Therapy Due to Apoptosis: Galectin-9. <i>International Journal of Molecular Sciences</i> , 2017, 18, 74.	4.1	58
72	Evaluation of in vivo efficacy of radiofrequency ablation with D-sorbitol in animal liver. <i>Molecular and Clinical Oncology</i> , 2016, 4, 183-186.	1.0	2

#	ARTICLE	IF	CITATIONS
73	Successful mucosal incision-assisted biopsy for the histological diagnosis of duodenal lymphoma: A case report. <i>Oncology Letters</i> , 2016, 11, 531-534.	1.8	1
74	Metformin-suppressed differentiation of human visceral preadipocytes: Involvement of microRNAs. <i>International Journal of Molecular Medicine</i> , 2016, 38, 1135-1140.	4.0	18
75	Chronic hepatitis B which converting to HBs antigen negativity and HBs antibody positivity during Peg-IFN α -2a treatment after surgery for hepatocellular carcinoma: a case report. <i>Acta Hepatologica Japonica</i> , 2016, 57, 666-673.	0.1	0
76	Galectin-9: An anticancer molecule for gallbladder carcinoma. <i>International Journal of Oncology</i> , 2016, 48, 1165-1174.	3.3	29
77	Diabetes mellitus and metformin in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 6100.	3.3	61
78	Primary hepatic neuroendocrine tumor: A case report. <i>Molecular and Clinical Oncology</i> , 2016, 4, 954-956.	1.0	15
79	Mechanism of gemcitabine-induced suppression of human cholangiocellular carcinoma cell growth. <i>International Journal of Oncology</i> , 2015, 47, 1293-1302.	3.3	20
80	Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo. <i>International Journal of Oncology</i> , 2015, 46, 2419-2430.	3.3	61
81	Laparoscopic splenectomy for patients with liver cirrhosis: Improvement of liver function in patients with Child-Pugh class B. <i>Surgery</i> , 2015, 158, 1538-1544.	1.9	41
82	Development of pure endoscopic full-thickness resection with mechanical countertraction and double-armed bar suturing systems. <i>Gastrointestinal Endoscopy</i> , 2014, 79, 24-25.	1.0	7
83	Profile of microRNAs associated with aging in rat liver. <i>International Journal of Molecular Medicine</i> , 2014, 34, 1065-1072.	4.0	24
84	Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. <i>International Journal of Oncology</i> , 2014, 45, 322-332.	3.3	80
85	Reduction effect of bacterial counts by preoperative saline lavage of the stomach in performing laparoscopic and endoscopic cooperative surgery. <i>World Journal of Gastroenterology</i> , 2014, 20, 15763.	3.3	14
86	An effective and safe gastric endoscopic submucosal dissection in the right lateral position using an inverted overtube. <i>World Journal of Gastroenterology</i> , 2014, 20, 1623.	3.3	2
87	Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. <i>International Journal of Oncology</i> , 2013, , .	3.3	3
88	Giant cutaneous metastasis from hepatocellular carcinoma. <i>JGH Open</i> , 0, , .	1.6	0